The first commercial polyglutamic acid plant in the United States has been running for all of five months. Now the company behind it says it has the capital to grow.
Ecovia Bio, a Livonia, Michigan-based maker of biodegradable polymers, announced February 3 that it closed a Series B funding round led by Pointe Angels, a local angel investor club. The company declined to disclose how much it raised—a fairly common move for startups navigating competitive markets—but said the money will fund an expansion of its 20,000-square-foot manufacturing facility and help push operations toward full capacity by 2028.
It's a notable inflection point for a company that spent nearly a decade in the academic trenches before commissioning its first production line last September. Ecovia Bio, which quietly rebranded from Ecovia Renewables in May 2025, is betting that its fermentation-derived γ-PGA (gamma-polyglutamic acid) can displace the petrochemical polymers—polyacrylates, acrylamides—that currently dominate products ranging from face creams to disposable diapers.
Whether the market is ready to embrace that swap, at scale and at competitive prices, is the open question.
Following the Money
Pointe Angels, a Grosse Pointe-based investor network that reported record deal activity across Michigan startups in 2024, led the round. No other investors were named. The group has not disclosed terms.
"This funding will allow us to expand our manufacturing capacity at our Livonia facility and further develop our roadmap for additional production sites," CEO Kousay Said said in a press release. The latest raise builds on roughly $1.6 million in seed funding Ecovia pulled together in 2018, supplemented by about $1.5 million in National Science Foundation grants between 2015 and 2018.
That's a lean funding history for a company trying to crack industrial-scale biomanufacturing, though the undisclosed Series B figure suggests investors see enough traction—or enough regulatory tailwind—to double down.
What They're Selling
Ecovia's core offering sits on a γ-PGA platform. The company markets two main products: AzuraBase, a linear polymer used as a humectant in cosmetics and personal care; and AzuraGel, a cross-linked superabsorbent designed for hygiene products, agriculture, and water treatment applications.
The pitch hinges on performance and environmental credentials. Ecovia claims AzuraGel can absorb up to 300 times its weight in water—a figure that puts it in the ballpark of conventional superabsorbent polymers—and says the material achieved OECD 301B "ready biodegradable" certification, degrading 92.7% in 28 days. The products carry USDA biobased certification and, critically, break down without leaving microplastic residue.
Traditional superabsorbents, the kind stuffed into billions of diapers and sanitary pads globally, are petroleum-derived and fragment into persistent microplastics. Ecovia's materials don't. The company also asserts it can produce γ-PGA at 50% lower cost than conventional methods, though it has not published the methodology behind that comparison or identified the baseline it's using.
Ecovia spun out of University of Michigan research in 2014, founded by Dr. Jeremy Minty and Dr. Xiaoxia "Nina" Lin. The startup cut its teeth in the NSF I-Corps commercialization program in 2013 and later won the grand prize at AkzoNobel's Imagine Chemistry competition in 2017. Said, who joined as chief science officer in 2020, assumed the CEO role sometime after that—exact timing unclear.
Regulatory Winds, Market Realities
The Series B arrives as regulatory scrutiny of microplastics sharpens. The European Union's REACH microplastics restriction took effect in October 2023, triggering phased bans across product categories including cosmetics and personal care. Implementation guidance issued in April 2025 tightened compliance timelines, putting pressure on manufacturers to reformulate or face market exclusion.
Meanwhile, the scientific literature on microplastics grows darker. Researchers have detected the particles in human blood, placentas, even lung tissue. Whether that translates into genuine consumer demand—or corporate willingness to pay a premium for cleaner alternatives—remains less certain. Regulatory mandates tend to move faster than consumer behavior.
Still, it's the backdrop Ecovia is counting on. David Bloom, executive director of Pointe Angels, said in a statement that the investor group is "excited to support Ecovia Bio's growth" and sees the company as "well-positioned to meet the surging global demand for sustainable biopolymer solutions."
Surging demand is one way to frame it. Another might be: regulatory pressure creating reluctant buyers.
The Path Forward
Ecovia has pegged 2028 as the year it hits full operational capacity at its Livonia site. The company is also evaluating additional production locations, though it hasn't disclosed capacity targets, tonnage figures, or geographic priorities.
One existing relationship to watch: Seppic, a subsidiary of Air Liquide that invested in Ecovia's 2018 seed round and secured exclusive marketing rights for topical health and beauty products using the technology. Whether that partnership deepens as Ecovia scales—or whether new offtake agreements emerge—could signal how well the company is converting regulatory tailwinds into commercial contracts.
For now, the Series B is perhaps less about the specific dollar figure—undisclosed as it is—and more about validation. A decade of academic research, federal grants, and pilot-scale tinkering is beginning to translate into commercial infrastructure. The harder test lies ahead: proving the technology can compete on cost and performance when production scales and the scrutiny intensifies.
By 2028, investors will have their answer. So will the diaper industry.
